Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Registro de Caso Kerecis para SurgiBind: Reforço de Tecidos Moles

10 de novembro de 2026 atualizado por: Kerecis Ltd.

Resultados de qualidade e segurança: Registro prospectivo de acompanhamento de enxertos de pele de peixe acelular aprovados pela FDA em reforço de tecidos moles.

Registry Objectives The overall objective of the registry is to collect quality and safety data to assess the long-term outcomes of Kerecis Omega3 SurgiBind in surgical procedures to reinforce soft tissue and prevent surgical complications. The ultimate goal of the registry is to enhance the quality of care, patient outcomes and establish a resource to facilitate the use of fish skin in preventing surgical wound dehiscence and surgical site infection.

Visão geral do estudo

Status

Concluído

Intervenção / Tratamento

Descrição detalhada

This Registry is a non-experiment non-interventional case registry to collect quality and safety data on patients that have been treat with the Kerecis product SurgiBind as their regular operative plan from their health care provider.

Primary Objective To collect and quantify patient safety and quality outcomes on a commercially available FDA cleared product Kerecis Omega3 SurgiBind utilized in surgical treatment to reinforce soft tissue and preventing surgical complications (dehiscence and infection).

Secondary Objective To assess the applicable complications post-surgery following the use of fish skin regarding time to heal, time to physical therapy, length of stay, etc.

Registry Procedures Specific Training Prior to patient enrollment, the Sponsor will initiate in person or virtual site visit with participating sites to provide training to the physicians and their staff about the protocol, registry procedures and data entry. The Sponsor will implement a number of strategies to ensure the quality, consistency and interpretability of data recorded. Training, education and ongoing liaison with participating sites will be provided to support high quality data collection.

Recruitment of participants Patients contacting the participating site to schedule the appointment for consultation about their upcoming surgery will be informed about the registry and will be given the option to participate. When the patient comes to the clinic for their visit, information regarding registry participation will be provided by a qualified research staff member. This oral information will be provided while the person is in a private room. Patients can also be recruited through recommendation from their doctors and health care providers.

Data Collection When a subject enrolls in the registry, a unique subject identification number will be assigned. After registry enrollment, data will be collected by the registry physician or trained site personnel either during the routine clinical visit or by telephone contact.

Registry Duration Patients will remain active in the registry for a period of 12 months, no additional information will be collected after that time. Registry enrollment will be for a period of at least 2 years. Registry analysis will be completed in 3 years.

Data Management and Quality Plan Data De-identification Patients enroll in the registry will be assigned a unique subject identification number. This number will consist of ten characters for the registry protocol number, three digits for a site number and four digits for a sequentially assigned subject number (i.e., 0001, 0002, 0003, etc.).

Data Confidentiality, Storage, and Retention All clinicians and related medical staff involved in looking after patients during the study are bound by medical confidentiality and are obliged to comply with data protection follow all Health Information Portability and Accountability Act of 1996 (HIPAA) and Protected Health Information (PHI). Data security is compliance with applicable federal and state laws, rule and regulations, including HIPAA regulation. Research results relating to this study are intended for use in an anonymous form in scientific publications. Personnel who process, generate report or otherwise have contact with PHI must uphold the patient's rights to confidentiality and will be trained in HIPAA privacy and security. If individuals authorized to view records are not bound by medical confidentiality as mentioned above, personal data that come to their attention during checks are confidential under the Data Protection Act.

Data will be collected in a form of case report form (CRF) and entered into secure, web-based portal databases. All users of the databases will need to log in to the databases through a pre-configured username and password controlled by administrator of the system. The databases are housed and managed in an International Organization for Standardization (ISO) 27001 certified environment. Only authorized users and site administrator can see site-wide data. Surgeon Users can only see their procedure. The registry will contain a built-in exporting function to enable data extraction by participating sites to help clinicians review their practice and improve the services. The paper formed CRF will be stored in a locked file cabinet at the participating sites and will be shredded after 7 years post completion of the registry.

Data Quality The registry will implement several strategies to maintain data quality and consistency such as routine cleaning, quality check and periodic feedback. Training, education and ongoing liaison with participating sites will be provided to supporting high quality data collection.

Data Sharing Data can only be shared between participating sites upon request that will be reviewed and approved by the Registry staff. The shared data is only for the purpose of clinical practice improvements, training models and benefiting the patient wellbeing. The registry staff will also provide participating sites with site reports on a regular basis.

Tipo de estudo

Observacional

Inscrição (Real)

75

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Illinois
      • Crystal Lake, Illinois, Estados Unidos, 60014
        • Northern Illinois Foot and Ankle Specialists
    • New York
      • New York, New York, Estados Unidos, 10019
        • Mount Sinai
    • North Carolina
      • Greensboro, North Carolina, Estados Unidos, 27401
        • Cone Health OrthoCare Greensboro
    • Virginia
      • Arlington, Virginia, Estados Unidos, 22201
        • Kerecis

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 90 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Patients over the age of 18 that are scheduled for surgery and part of their surgical plan is to be treated with Kerecis SurgiBind product for soft tissue reinforcement.

Descrição

Inclusion Criteria:

  • Inclusion Criteria

    1. Age 18 and older

    2. Undergoing surgical procedure requiring soft tissue reinforcement with Kerecis Omega3 SurgiBind

      For example:

      1. Plastic reconstructive surgery
      2. Orthopedic surgery
      3. Cardiothoracic surgery
      4. Vascular Surgery
      5. General Surgery

      Exclusion Criteria:

    1. Participants who request not to be in the registry
    2. Life expectancy of less than 1 year

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: CASE_ONLY
  • Perspectivas de Tempo: PROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
All patients

All patients who meet inclusion/exclusion criteria

Kerecis Fish Skin Graft - SurgiBind

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Number of surgical complication: dehiscence, infection
Prazo: 12 months

quantify the number of patients who experience postoperative wound complications including dehiscence and infection. Patients undergoing surgical procedures and experience wound complications are captured. Wound dehiscence will be categorized as superficial or deep. Infection (if appears) will be identified and recorded. Wounds are considered infected if the wound margins are erythematous and have one or combined of the following: active purulence or necrosis of underlying soft tissues.

12 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Time to healing:
Prazo: 12 months

Time to healing: wounds are considered healed when the incision is completely epithelialized with no surrounding erythema

12 months
Time to physical therapy initiation
Prazo: 12 months

Time it takes for patient to begin physical therapy after the surgical procedure

12 months
Duration of physical therapy
Prazo: 12 months

How long patient required physical therapy after surgery

12 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

25 de março de 2022

Conclusão Primária (Real)

29 de outubro de 2024

Conclusão do estudo (Real)

3 de janeiro de 2025

Datas de inscrição no estudo

Enviado pela primeira vez

1 de junho de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

1 de junho de 2023

Primeira postagem (Real)

12 de junho de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

13 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • KS-0710

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Sim

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever